Selskabets formål er markedsføring og salg af diagnostiske instrumenter og ydelser til kliniske laboratorier, sygehuse, læger, m.v., samt al virksomhed som efter bestyrelsens skøn er beslægtet her med.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 377.3 mio. | 8.8 mio. | 141.7 mio. | 54.1 mio. | 103 | |
CVR: 28485085
Secondary names: OBI A/S
The financial health of ROCHE DIAGNOSTICS A/S shows signs of recovery after a challenging period. In 2024, the company reported revenue of 377.3 million DKK and a profit of 8.8 million DKK, marking a return to profitability following a loss of 1.2 million DKK in 2023. However, revenue has significantly declined from 802.3 million DKK in 2022 and 1.4 billion DKK in 2021, indicating a downward trend in sales. The equity position has improved to 54.1 million DKK in 2024, up from 46.7 million DKK in 2023, but remains a concern compared to previous years. Overall, while the company is stabilizing, its declining revenue and past equity challenges highlight the need for strategic adjustments within the competitive pharmaceutical distribution industry.
AI-generated summary
Compared to 405 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 43707795
CVR 35818790
CVR 33597037
CVR 42683787
CVR 44740087
13 public tenders won
Showing 10 of 13 contracts
Sources: TED (the EU tender database) and udbud.dk
Esther Regina de Rooij joined the board
Bernard Maurice Georges Colombo left the board
Carole Hassoun joined the board
Darine Ghanem left the board
companydata.dk